LTR Pharma (ASX:LTP) EPS (Diluted): A$-0.05 (TTM As of Dec. 2025)


ASX:LTP LTR Pharma Ltd ASX:LTP
15 GF Score
Price A$0.58
View Full Analysis

What is LTR Pharma EPS (Diluted)?

LTR Pharma ASX:LTP +3.57% 15 EPS (Diluted) is A$-0.05 as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100.

LTR Pharma's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was A$-0.03. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.05.

LTR Pharma's EPS (Basic) for the six months ended in Dec. 2025 was A$-0.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.05.

LTR Pharma's EPS without NRI for the six months ended in Dec. 2025 was A$-0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.05.

During the past 3 years, the average EPS without NRIGrowth Rate was -67.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, LTR Pharma's highest 3-Year average EPS without NRI Growth Rate was -67.70% per year. The lowest was -67.70% per year. And the median was -67.70% per year.

LTR Pharma  (ASX:LTP) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

LTR Pharma EPS (Diluted) Related Terms

LTR Pharma EPS (Diluted) Historical Data

* Premium members only.

The historical data trend for LTR Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma EPS (Diluted) Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Diluted)
0.00 -0.01 -0.01 -0.05 -0.03

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Diluted) Get a 7-Day Free Trial -0.02 -0.03 -0.02 -0.02 -0.03

ASX:LTP vs VRTX, REGN, ALNY: EPS (Diluted) Comparison

For the Biotechnology subindustry, LTR Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where LTR Pharma's PE Ratio falls into.


ASX:LTP
15GF Score
LTR Pharma Ltd ASX:LTP
EPS (Diluted) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

LTR Pharma's Diluted EPS for the fiscal year that ended in Jun. 2025 is calculated as

Diluted EPS (A: Jun. 2025 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-5.594-0)/167.250
=-0.03

LTR Pharma's Diluted EPS for the quarter that ended in Dec. 2025 is calculated as

Diluted EPS (Q: Dec. 2025 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-5.761-0)/181.322
=-0.03

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Diluted) →
What does a EPS (Diluted) of A$-0.05 mean?
LTR Pharma (ASX:LTP) has a EPS (Diluted) of A$-0.05 as of Dec. 2025. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on LTR Pharma and its competitors.
Is LTR Pharma's EPS (Diluted) too high?
LTR Pharma's current EPS (Diluted) is A$-0.05. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's EPS (Diluted) compare to VRTX and REGN?
LTR Pharma's EPS (Diluted) of A$-0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Biotechnology company?
A good EPS (Diluted) depends on the Biotechnology industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on LTR Pharma and its competitors. LTR Pharma's current EPS (Diluted) is A$-0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current EPS (Diluted) of A$-0.05. The current EPS (Diluted) is A$-0.05. LTR Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current EPS (Diluted) is A$-0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score

Get the complete analysis for ASX:LTP

EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.58
Price